Published in Cancer on June 01, 1977
Tumour markers in breast cancer. Br J Cancer (1979) 1.13
An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer (1990) 1.07
Elevated CA125 levels in patients with metastatic breast carcinoma. Br J Cancer (1990) 0.96
Monitoring serum CEA in women with primary breast tumours positive for oestrogen receptor and with spread to lymph nodes. J Clin Pathol (1985) 0.87
Biological considerations in the treatment of early carcinoma of the breast and their role in the selection of therapy. Ann R Coll Surg Engl (1980) 0.78
Carcinoembryonic antigen in patients with breast or colon cancer. West J Med (1978) 0.76
Carcinoembryonic antigen in serum of unselected breast-cancer patients and of non-hospitalized controls. Br J Cancer (1979) 0.76
The clinical value of immunohistochemically demonstrable CEA in breast cancer: a possible method of selecting patients for adjuvant chemotherapy. Br J Cancer (1982) 0.75
Expression of human chorionic gonadotropin beta in gastric carcinoma: A retrospective immunohistochemical study. Indian J Med Paediatr Oncol (2009) 0.75
Possible surface protein markers for breast cancer. Br J Cancer (1981) 0.75
Tumour markers in breast cancer. Br Med J (1979) 0.75
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med (1980) 6.12
Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med (1976) 5.86
Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol (1996) 4.92
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (1990) 4.08
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA (1994) 4.01
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A (1998) 3.35
A comparison of two phase I trial designs. Stat Med (1994) 2.71
Survival of recipients of livers from donation after circulatory death who are relisted and undergo retransplant for graft failure. Am J Transplant (2014) 2.67
Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol (1974) 2.57
A scientific registry of transplant recipients bayesian method for identifying underperforming transplant programs. Am J Transplant (2014) 2.35
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol (1999) 2.22
Characterizing dye bias in microarray experiments. Bioinformatics (2005) 2.15
OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant (2015) 2.11
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. J Clin Oncol (1989) 2.02
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant (2014) 2.01
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med (1983) 1.97
Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med (1995) 1.91
Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol (1991) 1.91
Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl (2006) 1.88
OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant (2013) 1.84
Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch Neurol (1998) 1.82
OPTN/SRTR 2013 Annual Data Report: liver. Am J Transplant (2015) 1.79
Serotonin, Norepinephrine, and Related Compounds in Bananas. Science (1958) 1.75
An assay for the mitogenic activity of phytohemagglutinin preparations. Blood (1965) 1.73
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer (1978) 1.71
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med (1979) 1.61
The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer (1997) 1.60
OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant (2014) 1.59
Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol (1993) 1.55
Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann Surg (1977) 1.55
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol (1992) 1.55
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
Identification of transferrin as a lymphocyte growth promoter in human serum. Exp Cell Res (1972) 1.48
OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant (2013) 1.48
Quantitative high-performance liquid chromatography of nucleosides in biological materials. J Chromatogr (1978) 1.48
Effect of comorbidity adjustment on CMS criteria for kidney transplant center performance. Am J Transplant (2009) 1.43
Optimizing the program-specific reporting of pancreas transplant outcomes. Am J Transplant (2013) 1.40
A method for the evaluation of dose-toxicity relationships in clinical trials. Stat Med (1989) 1.39
Methotrexate pneumonitis: case report and review of the literature. Thorax (1972) 1.38
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
High turnover rate of transfer RNA in tumor tissue. Cancer Res (1977) 1.37
Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant (2010) 1.36
Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer (1982) 1.32
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol (1996) 1.31
Biological markers in breast carcinoma. I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides. Cancer (1975) 1.30
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys (1998) 1.29
Effect of prednisolone on synthesis of DNA and RNA by human lymphocytes in vitro. Nature (1967) 1.29
Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat (1988) 1.29
Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer (1982) 1.27
Sample size requirements for comparing time-to-failure among k treatment groups. J Chronic Dis (1982) 1.26
Application of a human tumor colony-forming assay to new drug screening. Cancer Res (1985) 1.26
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (1989) 1.25
Kidney, pancreas and liver allocation and distribution in the United States. Am J Transplant (2012) 1.24
Quantitative studies of phytohemagglutinin-induced DNA and RNA synthesis in normal and agammaglobulinemic leukocytes. J Exp Med (1967) 1.23
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. J Clin Oncol (1998) 1.21
OPTN/SRTR 2011 Annual Data Report: lung. Am J Transplant (2013) 1.20
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res (1988) 1.19
Pentamidine: clinical pharmacologic correlations in man and mice. Clin Pharmacol Ther (1970) 1.19
Clinical correlation between CEA and breast cancer. Cancer (1978) 1.19
Report of a consensus conference on transplant program quality and surveillance. Am J Transplant (2012) 1.18
Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med (1979) 1.18
Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst (1991) 1.16
Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep (1985) 1.15
Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol (1993) 1.14
Steroid hormone receptors in normal human lymphocytes. Induction of glucocorticoid receptor activity by phytohemagglutinin stimulation. J Biol Chem (1977) 1.13
Bayesian methods for assessing transplant program performance. Am J Transplant (2014) 1.12
Evaluating treatments when a gender by treatment interaction may exist. Stat Med (1997) 1.10
Combined chemotherapy and surgery in breast cancer: a review. Cancer (1975) 1.09
Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma. Can Med Assoc J (1973) 1.09
tRNA breakdown products as markers for cancer. Cancer (1979) 1.09
Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med (1983) 1.09
Effects of 5-fluorouracil on the cell kinetic and growth parameters of hepatoma 3924A. Br J Cancer (1975) 1.08
The bone marrow examination in breast cancer: diagnostic considerations and clinical usefulness. Cancer (1978) 1.08
Sample size considerations for non-randomized comparative studies. J Chronic Dis (1980) 1.08
OPTN/SRTR 2012 Annual Data Report: heart. Am J Transplant (2014) 1.08
Biological effects of transferrin on human lymphocytes in vitro. Exp Cell Res (1972) 1.07
Advanced ovarian cancer: correlation of histologic grade with response to therapy and survival. Cancer (1980) 1.07
OPTN/SRTR 2012 Annual Data Report: lung. Am J Transplant (2014) 1.07
Increasing incidence of Gram-positive sepsis in cancer patients. Med Pediatr Oncol (1978) 1.05
An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer (1983) 1.05
Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep (1981) 1.04
he determination of pentamidine (4,4'-diamidinophenoxypentane) in plasma, urine, and tissues. J Lab Clin Med (1970) 1.03
Biological markers in breast carcinoma. II. Clinical correlations with human chorionic gonadotrophin. Cancer (1977) 1.03
Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res (1987) 1.02
Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol (1988) 1.02
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. Am J Clin Oncol (1984) 1.02
Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat Rep (1976) 1.01
OPTN/SRTR 2013 Annual Data Report: lung. Am J Transplant (2015) 1.01